Guillain-Barré syndrome (GBS) is an immune-mediated polyradiculoneuropathy. It is recognized as a serious condition, because it includes dysautonomia and respiratory affection. In fact, there have been an increasing number of reports about GBS vaccine-related vaccinations as the COVID-19 vaccination campaign goes on. Here, we report two cases of Guillain-Barré syndrome (GBS) following the first dose of the Oxford/AstraZeneca COVID-19 vaccine. Symptoms appeared 21 days after vaccination, with acute progressive bilateral symmetric ascending flaccid tetra-paresis. The electromyography was compatible with a motor demyelinating polyneuropathy, confirming the diagnosis of the Guillain-Barré syndrome. Management with intravenous immunoglobulin was prescribed, with favorable outcomes. Clinical and laboratory tests confirmed the Guillain-Barré syndrome and the period from the date of vaccination to the appearance of initial symptoms, added to the absence of other causes, allowed to assume that the vaccination could be the cause. The literature is still unable to determine the pathogenesis of GBS due to COVID-19 vaccination. However, the findings underscore the importance of continuous surveillance and investigation into potential adverse effects of COVID-19 vaccines, emphasizing the need for informed decision-making and vigilant monitoring in vaccination campaigns.
Cite this paper
Benlamkadam, S. , Naji, Y. , Zakaria, Y. , Louhab, N. , Chraa, M. and Kissani, N. (2024). Guillain-Barré Syndrome Following AstraZeneca COVID-19-Vaccination: Two Cases Report Study. Open Access Library Journal, 11, e1356. doi: http://dx.doi.org/10.4236/oalib.1111356.
Tepe, S., Ku, T. and Mulyala, R. (2016) Acute Descending Paralysis Secondary to Variant GBS. Chest, 150, Article 1080. https://doi.org/10.1016/j.chest.2016.08.1187
Chung, J.Y., Thone, M.N. and Kwon, Y.J. (2021) COVID-19 Vaccines: The Status and Perspectives in Delivery Points of View. Advanced Drug Delivery Reviews, 170, 1-25. https://doi.org/10.1016/j.addr.2020.12.011
Yesuf, E.A., Riad, A., Sofi-Mahmudi, A., Sudhakar, M., Mekonnen, A., Endalkachew, S., Mama, F., et al. (2022) Self-Reported Side Effects of the Oxford AstraZeneca COVID-19 Vaccine among Healthcare Workers in Ethiopia, Africa: A Cross-Sectional Study. Frontiers in Public Health, 10, Article ID: 937794. https://doi.org/10.3389/fpubh.2022.937794
Abolmaali, M., Rezania, F., Behnagh, A.K., Hamidabad, N.M., Gorji, A. and Mirzaasgari, Z. (2022) Guillain-Barré Syndrome in Association with COVID?19 Vaccination: A Systematic Review. Immunologic Research, 70, 752-764. https://doi.org/10.1007/s12026-022-09316-6
Kilinc, D., Pasch, S., Doets, A.Y., Jacobs, B.C., Vliet, J. and Garssen, M.P.J. (2020) Guillain-Barré Syndrome after SARS-CoV-2 Infection. European Journal of Neurology, 27, 1757-1758. https://doi.org/10.1111/ene.14398
Sedaghat, Z. and Karimi, N. (2020) Guillain Barre Syndrome Associated with COVID-19 Infection: A Case Report. Journal of Clinical Neuroscience, 76, 233-235. https://doi.org/10.1016/j.jocn.2020.04.062
Introna, A., Caputo, F., Santoro, C., Guerra, T., Ucci, M., Mezzapesa, D.M. and Trojano, M. (2021) Guillain-Barré Syndrome after AstraZeneca COVID-19-Vaccination: A Causal or Casual Association? Clinical Neurology and Neurosurgery, 208, Article ID: 106887. https://doi.org/10.1016/j.clineuro.2021.106887
Yu, M., Nie, S., Qiao, Y. and Ma, Y. (2023) Guillain-Barré Syndrome Following COVID-19 Vaccines: A Review of Literature. Frontiers in Immunology, 14, Article ID: 1078197. https://doi.org/10.3389/fimmu.2023.1078197
Hill, A. (1965) The Environment and Disease: Association or Causation? Journal of the Royal Society of Medicine, 58, 295-300. https://doi.org/10.1177/003591576505800503
GBS/CIDP Foundation International (2021) Foundation Global Medical Advisory Board Statement on COVID Vaccines for CIDP and MMN. https://www.gbs-cidp.org/2021/01/foundation-global-medical-advisory-board-statement-on-covid-vaccines-for-cidp-and-mmn/